Claims for Patent: 10,555,938

Summary for Patent: 10,555,938

Title:	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Abstract:	The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
Inventor(s):	Rader; Daniel J. (Philadelphia, PA)
Assignee:	The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:	16/030,703
Patent Claims:	1. A method of treating a subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the subject an effective amount of an MTP inhibitor, wherein said administration of the MTP inhibitor comprises three step-wise, increasing dose levels of the MTP inhibitor; wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2- -yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9-carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor reduces low-density lipoprotein cholesterol of the subject by at least 30% as compared to control blood levels. 2. The method of claim 1, wherein the subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia. 3. The method of claim 1, wherein the first dose level is sub-therapeutic. 4. The method of claim 1, wherein the administration of the MTP inhibitor further comprises a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level. 5. The method of claim 1, wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a subject at a starting dose of 25 mg/day. 6. A method of treating a subject suffering from hyperlipidemia or hypercholesterolemia the method comprising administering to the subject an effective amount of an MTP inhibitor, wherein said administration of the MTP inhibitor comprises at least three step-wise, increasing dose levels of the MTP inhibitor; wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2- -yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9-carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor reduces apolipoprotein B level of the subject by at least 30% as compared to control blood levels. 7. The method of claim 6, wherein the subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia. 8. The method of claim 6, wherein the first dose level is sub-therapeutic. 9. The method of claim 6, wherein the administration of the MTP inhibitor further comprise a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level. 10. The method of claim 6, wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a subject at a starting dose of 25 mg/day. 11. The method of claim 6, wherein the administration of the MTP inhibitor reduces total cholesterol of the subject by at least 30% as compared to control blood levels. 12. A method of treating a subject suffering from hyperlipidemia or hypercholesterolemia, the method comprising administering to the subject an effective amount of an MTP inhibitor, wherein said administration of the MTP inhibitor comprises three step-wise, increasing dose levels of the MTP inhibitor; wherein each of the dose levels is no more than 50% of the immediately following dose level; wherein each of the dose levels is administered for about 1 to about 12 weeks; wherein the MTP inhibitor is N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2- -yl] carbonyl] amino]-1-piperidinyl]butyl]-9H-fluorene-9-carboxamide, methanesulfonate; and wherein the administration of the MTP inhibitor reduces triglyceride level of the subject by at least 30% as compared to control blood levels. 13. The method of claim 12, wherein the subject suffering from hyperlipidemia or hypercholesterolemia has homozygous familial hypercholesterolemia. 14. The method of claim 12, wherein the first dose level is sub-therapeutic. 15. The method of claim 12, wherein the administration of the MTP inhibitor minimizes side effects as compared to administration of the MTP inhibitor to a subject at a starting dose of 25 mg/day. 16. The method of claim 12, wherein the administration of the MTP inhibitor reduces total cholesterol of the subject by at least 30% as compared to control blood levels. 17. The method of claim 12, wherein the administration of the MTP inhibitor further comprises a fourth dose level, and wherein the third dose level is no more than 50% of the fourth dose level.